Psychiatr. pro Praxi, 2008; 9(2): 89-90

Prozac (fluoxetin) - nová, schválená indikace pro dětskou psychiatrii v ČR

prof. MUDr. Ivana Drtílková CSc
Psychiatrická klinika LF MU a FN Brno

Prozac (fluoxetin) byl oficiálně schválen pro léčbu deprese u dětí a adolescentů v České republice v červnu 2007.

Léčba antidepresivy by neměla být nabízena dětem a mladým osobám se středně těžkou až těžkou depresí bez souběžně prováděné psychoterapie. V souladu s vodítky léčby NICE, jestliže je u dětí nebo mladistvých se středně těžkou až těžkou depresí ordinováno antidepresivum, by měl být použit fluoxetin, který v klinických studiích prokázal převahu prospěchu nad riziky léčby.

Keywords: deprese, děti, adolescenti, fluoxetin, Prozac

Published: April 15, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I. Prozac (fluoxetin) - nová, schválená indikace pro dětskou psychiatrii v ČR. Psychiatr. praxi. 2008;9(2):89-90.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Emslie GJ, Rish AJ, Weiberg WA et al. A double-blind randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch gen Psychiatry 1997; 54: 1031-1037. Go to original source... Go to PubMed...
    2. Emslie GJ, Heilingeistein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo controlled, randomized clinical trial. J Am Acad Adolsc Psychiatry 2002; 41: 1205-1215. Go to original source... Go to PubMed...
    3. FDA schedules review for antidepressant/suicidality issue. Child and Adolescent Psychopharmacology 2004; (6)9: 6-8.
    4. Drtílková I. Klinická vodítka NICE léčby depresivních poruch u dětí a adolescentů. Psychiat. pro Praxi 2007; 4: 158-161.
    5. Kratochvil CH, Vitiello B, Brent D et al. Selecting an antidepressants for the treatment of pediatric depression. J. Am. Acad. Child Adoles. Psychiatry 2006; 45(3): 371-373. Go to original source... Go to PubMed...
    6. National Institute for Health and Clinical Excelence (NICE). Depression in children and young people. Clinical Guidelines 28, September 2005. Dostupné: www.nice.org.uk/pdf/CGO28NICE guideline.pdf.
    7. SÚKL. Přehodnocení rizik antidepresiv ze skupiny SSRI a SNRI. Farmakoterap Inf 2005a; (1): 3.
    8. TADS study update: Fluoxetin plus CBT offers most favorable risk/benefit trade off for adolescents with MDD. Child and Adolescent Psychopharmacology 2004; 6(9): 1-4.
    9. Whittington C, Kendall T, Fongay P. SSRI in chilhood depression: systematic review of published versus unpublished data. The Lancet 2004; 363(4): 1341-1345. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.